Methotrexate

Discussion of Methotrexate Dosage
Sinead A Maguire, Claire Marie Sheehy

Annals of the Rheumatic Diseases Aug 2018, 77 (8) e47; DOI: 10.1136/annrheumdis-2017-212358
Response to eLetter: ‘Discussion of methotrexate dosage’ by Maguire et al
Mary Safy, J W G Jacobs, Nicole D Ijff, J W J Bijlsma, J M van Laar, Maria J H de Hair

Annals of the Rheumatic Diseases Aug 2018, 77 (8) e48; DOI: 10.1136/annrheumdis-2017-212380
Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative
Tamas Constantin, Ivan Foeldvari, Jordi Anton, Joke de Boer, Severine Czitrom-Guillaume, Clive Edelsten, Raz Gepstein, Arnd Heiligenhaus, Clarissa A Pilkington, Gabriele Simonini, Yosef Uziel, Sebastian J Vastert, Nico M Wulffraat, Anne-Mieke Haasnoot, Karoline Walscheid, Annamária Pálinkás, Reshma Pattani, Zoltán Györgyi, Richárd Kozma, Victor Boom, Andrea Ponyi, Angelo Ravelli, Athimalaipet V Ramanan

Annals of the Rheumatic Diseases Aug 2018, 77 (8) 1107-1117; DOI: 10.1136/annrheumdis-2018-213131
Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA
Jens Klotsche, Kirsten Minden, Martina Niewerth, Gerd Horneff

Annals of the Rheumatic Diseases Jul 2018, 77 (7) 996-1002; DOI: 10.1136/annrheumdis-2017-211968
Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial
Jin Kyun Park, Yun Jong Lee, Kichul Shin, You-Jung Ha, Eun Young Lee, Yeong Wook Song, Yunhee Choi, Kevin L Winthrop, Eun Bong Lee

Annals of the Rheumatic Diseases Jun 2018, 77 (6) 898-904; DOI: 10.1136/annrheumdis-2018-213222
Methotrexate limits inflammation through an A20-dependent cross-tolerance mechanism
Cristina Municio, Ángeles Dominguez-Soto, Sara Fuentelsaz-Romero, Amalia Lamana, Nuria Montes, Víctor D Cuevas, Raquel García Campos, José L Pablos, Isidoro González-Álvaro, Amaya Puig-Kröger

Annals of the Rheumatic Diseases May 2018, 77 (5) 752-759; DOI: 10.1136/annrheumdis-2017-212537
Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate
Hiroaki Matsuno, Masato Tomomitsu, Atsushi Hagino, Seonghye Shin, Jiyoon Lee, Yeong Wook Song

Annals of the Rheumatic Diseases Apr 2018, 77 (4) 488-494; DOI: 10.1136/annrheumdis-2017-212172
Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis
Arthur Kavanaugh, Ronald F van Vollenhoven, Roy Fleischmann, Paul Emery, Iain Sainsbury, Stefan Florentinus, Su Chen, Benoît Guérette, Hartmut Kupper, Josef S Smolen

Annals of the Rheumatic Diseases Feb 2018, 77 (2) 289-292; DOI: 10.1136/annrheumdis-2017-211871
Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate
Joel M Kremer, Michael E Weinblatt

Annals of the Rheumatic Diseases Jan 2018, 77 (1) e4; DOI: 10.1136/annrheumdis-2017-211632
Response to: Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis by Kremer and Weinblatt
Jenny H Humphreys, Ruth Costello, Suzanne MM Verstappen, William G Dixon

Annals of the Rheumatic Diseases Jan 2018, 77 (1) e5; DOI: 10.1136/annrheumdis-2017-211670

Main menu

Methotrexate

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Methotrexate

Pages